Application Note: Analysis of a New High Throughput Screening Detection Technology for Rapid hERG Safety Testing Using a Fluorescence Polarization Assay
21 October 2012
The vast majority of drugs associated with acquired QT prolongation are known to interact with hERG. In this application note from BioTek, the use if the Synergy™ Neo HTS detection platform for hERG screening via a fluorescence polarization based assay is described. Using assay controls and a panel of multiple hERG inhibitors, analysis of pharmacology endpoints for instrument validation include Z’, assay window, precision and plate read times. Additionally, FP-based IC50 data is generated and compared to data from traditional electrophysiological and radiometric methods.